Literature DB >> 21889879

The roles of P- and E-selectins and P-selectin glycoprotein ligand-1 in primary and metastatic mouse melanomas.

Toshifumi Yamaoka1, Manabu Fujimoto, Fumihide Ogawa, Ayumi Yoshizaki, Sang Jae Bae, Eiji Muroi, Kazuhiro Komura, Yohei Iwata, Yuichiro Akiyama, Koichi Yanaba, Kazuhiro Shimizu, Shinichi Sato.   

Abstract

BACKGROUND: Malignant melanoma is often accompanied by a host response of inflammatory cell infiltration that is highly regulated by multiple adhesion molecules.
OBJECTIVE: To evaluate the role of adhesion molecules, including P-selectin glycoprotein ligand-1 (PSGL-1), P-selectin, and E-selectin.
METHODS: Subcutaneous primary growth and metastasis to the lung of B16 melanoma cells were examined in mice lacking PSGL-1, P-selectin, or E-selectin.
RESULTS: Primary subcutaneous growth of B16 melanoma was augmented by loss of PSGL-1, P-selectin, or E-selectin, while pulmonary metastasis was reduced by the loss of E-selectin. The enhancement of subcutaneous tumor growth was associated with a reduced accumulation of natural killer cells, CD4(+) T cells and CD8(+) T cells, while the attenuation of pulmonary metastasis was related to the numbers of CD8(+) T cells. The expressions of transforming growth factor (TGF)-β and interleukin (IL)-6 were correlated with primary subcutaneous growth; TGF-β, IL-6, and interferon-γ were related to number of metastatic lung nodules. Cytotoxicity against melanoma cells in splenocytes and in tumor-draining lymph node cells were not defective by the absence of adhesion molecules, suggesting that the enhancement of tumor growth and metastasis caused by the loss of selectins results from an impaired migration of effector cells into the tissue.
CONCLUSIONS: The results indicate the complexity of anti-tumor responses mediated by adhesion molecules in primary subcutaneous tumors and pulmonary metastasis of murine experimental melanoma.
Copyright © 2011 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21889879     DOI: 10.1016/j.jdermsci.2011.07.005

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  6 in total

Review 1.  PSGL-1: A New Player in the Immune Checkpoint Landscape.

Authors:  Roberto Tinoco; Dennis C Otero; Amy A Takahashi; Linda M Bradley
Journal:  Trends Immunol       Date:  2017-03-02       Impact factor: 16.687

2.  Pilot study on "pericytic mimicry" and potential embryonic/stem cell properties of angiotropic melanoma cells interacting with the abluminal vascular surface.

Authors:  Claire Lugassy; Madhuri Wadehra; Xinmin Li; Mirko Corselli; David Akhavan; Scott W Binder; Bruno Péault; Alistair J Cochran; Paul S Mischel; Hynda K Kleinman; Raymond L Barnhill
Journal:  Cancer Microenviron       Date:  2012-12-29

3.  Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells.

Authors:  Zhi-Qiang Wang; Mamadou Keita; Magdalena Bachvarova; Stephane Gobeil; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

4.  SSeCKS/Akap12 suppresses metastatic melanoma lung colonization by attenuating Src-mediated pre-metastatic niche crosstalk.

Authors:  Masashi Muramatsu; Shin Akakura; Lingqiu Gao; Jennifer Peresie; Benjamin Balderman; Irwin H Gelman
Journal:  Oncotarget       Date:  2018-09-11

Review 5.  PSGL-1 Immune Checkpoint Inhibition for CD4+ T Cell Cancer Immunotherapy.

Authors:  Julia M DeRogatis; Karla M Viramontes; Emily N Neubert; Roberto Tinoco
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

6.  Docking of THPDTPI: to explore P-selectin as a common target of anti-tumor, anti-thrombotic and anti-inflammatory agent.

Authors:  Haimei Zhu; Yuji Wang; Ce Song; Qiqi Feng; Jianhui Wu; Shurui Zhao; Lin Gui; Xiaoyi Zhang; Ming Zhao; Shiqi Peng
Journal:  Oncotarget       Date:  2017-07-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.